Home › Funds › Kynam Capital Management, LP › BCRX
Kynam Capital Management, LP position in BCRX
BIOCRYST PHARMACEUTICALS INC · Health Care
Kynam Capital Management, LP reported holding 2,522,660 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$25.2M, representing 1.39% of its reported portfolio and ranking #18 among its reported holdings. Kynam Capital Management, LP has disclosed BCRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Kynam Capital Management, LP's BCRX position evolved
Kynam Capital Management, LP first disclosed a stake in BCRX in Q3 2023 at 3,133,193 shares (US$22.2M). The position peaked in Q2 2025 at 8,463,742 shares, worth US$75.8M. Across 12 filings, Kynam Capital Management, LP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 2,522,660 shares valued at US$25.2M — a reduction of -3,158,135 shares quarter over quarter.. Notable position changes include a 47% increase in Q4 2023 (shares fell 15% over the following quarter), a 42% increase in Q1 2024 (shares rose 22% over the following quarter), a 56% trim in Q2 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.13M | $22.18M | New |
| Q4 2023 | 4.60M | $27.55M | Add |
| Q1 2024 | 6.53M | $33.16M | Add |
| Q2 2024 | 8.83M | $54.55M | Add |
| Q3 2024 | 9.09M | $69.05M | Add |
| Q4 2024 | 9.09M | $68.32M | Hold |
| Q1 2025 | 8.93M | $66.96M | Reduce |
| Q2 2025 | 8.46M | $75.84M | Reduce |
| Q3 2025 | 9.39M | $71.27M | Add |
| Q4 2025 | 9.37M | $73.06M | Hold |
| Q1 2026 | 5.68M | $54.08M | Reduce |
| Q2 2026 | 2.52M | $25.23M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BCRX and 13F data
BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BCRX
- RA CAPITAL MANAGEMENT, L.P. 15.83M sh · $158.27M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 15.10M sh · $150.96M · Q2 2026
- TCG Crossover Management, LLC 11.02M sh · $110.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.31M sh · $103.09M · Q2 2026
- Vestal Point Capital, LP 8.30M sh · $83.00M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.01M sh · $40.09M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 2.33M sh · $23.32M · Q2 2026
- Nantahala Capital Management, LLC 1.90M sh · $19.01M · Q2 2026
- Eversept Partners, LP 1.87M sh · $18.66M · Q2 2026
- Parkman Healthcare Partners LLC 1.62M sh · $16.24M · Q2 2026
More on Kynam Capital Management, LP
FAQ
How long has Kynam Capital Management, LP held BCRX?
Kynam Capital Management, LP has disclosed BCRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Kynam Capital Management, LP's current position in BCRX?
As of Q2 2026, Kynam Capital Management, LP holds 2.52M shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $25.23M, representing 1.39% of its reported portfolio and ranking #18.
Has Kynam Capital Management, LP been buying or selling BCRX?
In the latest 13F filing (Q2 2026), Kynam Capital Management, LP reduced its position in BCRX. The position peaked in Q2 2025 at 8.46M shares.
Which other funds hold BCRX?
Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.